Table 4 Comparison of the clinical variables of patients with positive and negative mpMRI and 18F-CH PET/CT
mpMRI | 18F-CH PET/CT | |||||
|---|---|---|---|---|---|---|
Positive n = 21 | Negative/Uncertain n = 17 | P value | Positive n = 20 | Negative/Uncertain n = 18 | P value | |
Age, years | 63,2 ± 7,2 | 62,5 ± 7,4 | 0,767 | 63,4 ± 7,6 | 62,4 ± 6,8 | 0,703 |
Preoperative PSA, ng/mL | 7,7 [14,0] | 7,0 [8,4] | 0,453 | 7,4 [9,1] | 7,5 [12,1] | 0,65 |
Pathologic T stage (%) | ||||||
T2 | 11 (44,0) | 14 (56,0) | 0,086 | 11 (44,0) | 14 (56,0) | 0,182 |
T3 | 10 (76,9) | 3 (23,1) | 9 (69,2) | 4 (30,8) | ||
Pathologic N stage, n (%) | ||||||
N0 | 9 (56,3) | 7 (43,8) | 0,917 | 10 (62,5) | 6 (37,5) | 0,299 |
Nx | 12 (54,5) | 10 (45,5) | 10 (45,5) | 12 (54,5) | ||
Pathologic Gleason score, n (%) | ||||||
≤ 7 | 13 (46,4) | 15 (53,6) | 0,136 | 11 (39,3) | 17 (60,7) | 0,009 |
> 7 | 8 (80,0) | 2 (20,0) | 9 (90,0) | 1 (10,0) | ||
Positive surgical margin, n (%) | ||||||
Yes | 8 (50,0) | 8 (50,0) | 0,578 | 6 (37,5) | 10 (62,5) | 0,111 |
No | 13 (59,1) | 9 (40,9) | 14 (63,6) | 8 (36,4) | ||
Perineural Invasion, n (%) | ||||||
Yes | 10 (58,8) | 7 (41,2) | 0,691 | 9 (52,9) | 8 (47,1) | 0,973 |
No | 11 (52,4) | 10 (47,6) | 11 (52,4) | 10 (47,6) | ||
Lymphatic vessel invasion, n (%) | ||||||
Yes | 2 (50,0) | 2 (50,0) | 1,000 | 2 (50,0) | 2 (50,0) | 1,000 |
No | 19 (55,9) | 15 (44,1) | 18 (52,9) | 16 (47,1) | ||
PSA levels, ng/mL | ||||||
Post radical prostatectomy | 0,2 [1,4] | 0,0 [0,1] | 0,006 | 0,2 [1,3] | 0,0 [0,1] | 0,007 |
On day of biochemical failure | 0,9 [1,2] | 0,4 [0,1] | 0,005 | 0,7 [1,1] | 0,4 [0,1] | 0,009 |
On day of CH PET/CT and mpMRI | 2,0 [1,9] | 0,4 [1,0] | 0,024 | 2,0 [1,7] | 0,4 [0,7] | 0,019 |
Lowest PSA level after surgery | 0,2 [1,4] | 0,0 [0,1] | 0,012 | 0,2 [1,2] | 0,0 [0,1] | 0,003 |
Treatment before mpMRI/18F-CH PET, n (%) | ||||||
Radical prostatectomy only | 14 (51,9) | 13 (48,1) | 0,508 | 15 (55,6) | 12 (44,4) | 0,572 |
Prostatectomy and HT or RT | 7 (63,6) | 4 (36,4) | 5 (45,5) | 6 (54,5) | ||
Time from prostatectomy, months | ||||||
To first PSA recurrence | 5,0 [36,0] | 16,0 [18,5] | 0,075 | 5,5 [21,0] | 16,5 [25,0] | 0,079 |
To mpMRI/PET/CT | 31,0 [55,5] | 27,0 [44,5] | 0,596 | 10,5 [36,0] | 32,0 [48,0] | 0,187 |
PSA doubling time, months | 4,0 [9,5] | 5,8 [8,5] | 0,634 | 3,1 [5,3] | 8,5 [9,5] | 0,135 |